Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent.

Abstract	sanofi-aventis (formerly Sanofi-Synthelabo) is developing the oral class III anti-arrhythmic agent dronedarone (Multaq) for the potential treatment and prevention of atrial fibrillation. In June 2005, sanofi-aventis submitted EU and US filings for atrial fibrillation. In October 2002, phase I trials for arrhythmia were reported to be ongoing in Japan.
Authors	Sylvie Sablayrolles, Bruno Le Grand
Journal	Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 7 Issue 9 Pg. 842-9 (Sep 2006) ISSN: 1472-4472 [Print] England
PMID	17002263 (Publication Type: Journal Article, Review)
Chemical References	Anti-Arrhythmia Agents Dronedarone Amiodarone
Topics	Amiodarone (adverse effects, analogs & derivatives, chemical synthesis, pharmacokinetics, pharmacology, therapeutic use) Animals Anti-Arrhythmia Agents (adverse effects, chemical synthesis, pharmacokinetics, pharmacology, therapeutic use) Arrhythmias, Cardiac (drug therapy) Atrial Fibrillation (drug therapy) Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Dronedarone Humans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!